A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy

Trial Profile

A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Brazikumab (Primary) ; Brazikumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Allergan; MedImmune
  • Most Recent Events

    • 31 Mar 2017 Planned End Date changed from 1 Sep 2019 to 18 Jun 2019.
    • 31 Mar 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jan 2019.
    • 03 Oct 2016 Planned End Date changed from 1 Jul 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top